Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies
Cancer therapies are toxic. Newer oncological treatments such as immunotherapy produce unconventional adverse events that are collectively referred to as immune-related adverse events (irAEs). These irAEs are clinician-rated and typically reported via tabulation of adverse events from the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). However, the symptomatic effects of treatment and the severity of disease are best reported by the patient themselves. Although many pivotal trials for immunotherapeutic agents include health-related quality-of-life measures, symptom-focused assessments are more proximal to the effects of treatment and disease burden. This chapter discusses how best to measure symptoms, describes the desirable properties of a psychometrically valid symptom assessment tool, reviews available symptom assessment tools, provides methods to assist in the interpretation of PRO data, elucidates the feasibility and benefit of incorporating PRO in several cancer cohorts, describes the current use of PROs in immunotherapy, and identifies areas where further research are needed to enhance the use of PROs in cancer patients undergoing immunotherapy.
KeywordsPatient-reported outcomes Symptoms Immunotherapy Cancer
Conflicts of Interest
The author reports no conflict of interest in this work.
- 1.Patient-Reported Outcomes Measurement Information System. Welcome to PROMIS. Available from: http://www.nihpromis.org. Accessed 26 June 2018.
- 2.US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf. Accessed 26 June 2018.
- 3.Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9). pii: dju244.Google Scholar
- 4.de Haes JC. Quality of life: conceptual and theoretical considerations. In: Watson M, Greer S, Thomas C, editors. Psychosocial oncology. Oxford: Pergamon Press; 1988. p. 61–70.Google Scholar
- 8.Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;(37):16–21.Google Scholar
- 9.Crocker LM, Algina J. Introduction to classical and modern test theory. Pacific Grove: Wadsworth Publishing; 2006.Google Scholar
- 11.Nunnally JC, Bernstein IH. Psychometric theory, vol. 3. New York: McGraw-Hill; 1994. McGraw-Hill Series in PsychologyGoogle Scholar
- 12.American Educational Research Association, American Psychological Association, National Council on Measurement in Education, Joint Committee on Standards for Educational and Psychological Testing. Standards for educational and psychological testing. 2nd ed. Washington, DC: American Educational Research Association; 1999.Google Scholar
- 14.Willis GB, Reeve BB, Barofsky I, Invited Paper C. The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessment. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer: measures, methods and applications. Cambridge: Cambridge University Press; 2004. p. 610–22.CrossRefGoogle Scholar
- 17.Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Issues in pain measurement, vol. 12: Advances in pain research and therapy. New York: Raven Press; 1989. p. 391–403.Google Scholar
- 28.Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 29.Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, et al. Feasibility of patient reporting of symptomatic adverse events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. Int J Radiat Oncol Biol Phys. 2017;98(2):409–18.PubMedPubMedCentralCrossRefGoogle Scholar
- 40.Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Earlbaum; 1988.Google Scholar
- 48.Wang XS, Shi Q, Yue J, Chen TY, Xu T, Komaki R, et al. Predictive value of patient-reported outcomes on radiation pneumonitis related normal lung uptake of FDG on PET in patients with non-small cell lung cancer treated with concurrent chemoradiation [abstract 3015]. International Society for Quality of Life Research 23rd annual conference; Copenhagen, Denmark; Oct 19-22, 2016. Qual Life Res. 2016;25(Suppl 1):157–8.Google Scholar
- 51.Williams LA, Giralt SA, Wang XS, Mobley GM, Mendoza TR, Cohen MZ, et al., editors. Measuring the symptom burden of allogeneic hematopoietic stem cell transplantation in patients with and without acute graft-versus-host disease [abstract 49]. Biol Blood Marrow Transplant. 2009;15(Suppl 2):20–1.Google Scholar
- 54.Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, et al. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using The University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 2014;120(13):1975–84.PubMedPubMedCentralCrossRefGoogle Scholar
- 57.Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A. Patient-reported outcomes in OAK: a phase III study of Atezolizumab versus Docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018. pii: S1525-7304(18)30131-1. https://doi.org/10.1016/j.cllc.2018.05.011.
- 59.Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu SQ, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1 alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656–66.PubMedCrossRefGoogle Scholar
- 61.Mendoza TR, George G, Williams L, Shi Q, Naing A, Hong DS, et al, editors. Feasibility and added value of multiple baseline symptom assessments in early-phase clinical trials [abstract]. Presented at the International Society for Quality of Life Research (ISOQOL) 24th annual conference, Philadelphia; 2017.Google Scholar